Gilead Sciences Raises FY Guidance Due To Remdesivir Sales
*CNBC Exclusive: CNBC Transcript: Gilead Sciences Chairman & CEO [Daniel O’Day](https://www.valuewalk.com/2020/08/astrazeneca-acquire-gilead-sciences/) speaks with CNBC’s “Squawk Box” today about raising full\-year guidance due to remdesivir sales\.* Q3 2020 hedge fund letters, conferences and more Gilead Sciences CEO On Raising Full-Year Guidance Due To Remdesivir SalesMEG TIRRELL: Dan, thanks for being with us this morning. Let's start with your news of the day. You raised your guidance for the full year now because of your Remdesivir sales looking at now $2.83 billion. Tell us about this gu...